Provided by Tiger Fintech (Singapore) Pte. Ltd.

RxSIGHT, INC.

7.97
+0.03000.38%
Post-market: 7.990.0200+0.25%19:44 EDT
Volume:776.47K
Turnover:6.17M
Market Cap:323.88M
PE:-11.95
High:8.09
Open:8.00
Low:7.71
Close:7.94
Loading ...

Stock Track | RxSight Plummets 35.65% as Q2 Revenue Disappoints and 2025 Guidance Slashed

Stock Track
·
09 Jul

U.S. RESEARCH ROUNDUP-Bloom Energy, Ford, Tesla

Reuters
·
09 Jul

BUZZ-RxSight tumbles as company cuts 2025 sales forecast

Reuters
·
09 Jul

RxSight Preliminary Q2 Revenue Falls, Trims 2025 Guidance; Shares Decline

MT Newswires Live
·
09 Jul

RxSight Inc. Revises 2025 Revenue Guidance Downwards by Up to 14%, Reports 4% Drop in Q2 Sales

Reuters
·
09 Jul

Press Release: RxSight, Inc. Announces Preliminary Second Quarter 2025 Revenue and Revised 2025 Guidance

Dow Jones
·
09 Jul

Analysts’ Top Healthcare Picks: Sanofi (SNY), RxSight (RXST)

TIPRANKS
·
03 Jul

RxSight Re-elects Directors at Annual Meeting

TIPRANKS
·
05 Jun

RxSight Inc. Conducted Annual Meeting of Stockholders

Reuters
·
05 Jun

RxSight’s Positive Momentum and Strategic Growth Initiatives Support Buy Rating

TIPRANKS
·
01 Jun

RxSight Inc. to Participate in Stifel Virtual Ophthalmology Forum

Reuters
·
21 May

Sector Update: Health Care Stocks Advance Late Afternoon

MT Newswires Live
·
20 May

RxSight Shares Rise After Upgrade From Wells Fargo

MT Newswires Live
·
20 May

RxSight Raised to Overweight From Equal-Weight by Wells Fargo

Dow Jones
·
19 May

Wells Fargo Upgrades RxSight to Overweight From Equalweight, Lifts Price Target to $25 From $17

MT Newswires Live
·
19 May

RxSight’s Promising Market Position and Growth Potential: A Buy Recommendation by Larry Biegelsen

TIPRANKS
·
19 May

Medical Technology Firms Face Price Target Revisions From Morgan Stanley

MT Newswires Live
·
14 May

Morgan Stanley Adjusts Price Target on RxSight to $20 From $42, Maintains Overweight Rating

MT Newswires Live
·
13 May

Stock Track | RxSIGHT Stock Plummets 5.20% After BofA Slashes Price Objective

Stock Track
·
08 May

RxSight: Favorable Risk/Reward Scenario with Strong Growth Prospects and Attractive Valuation

TIPRANKS
·
08 May